DE60216078D1 - Opioid enthaltende arzneiform gegen missbrauch - Google Patents

Opioid enthaltende arzneiform gegen missbrauch

Info

Publication number
DE60216078D1
DE60216078D1 DE2002616078 DE60216078A DE60216078D1 DE 60216078 D1 DE60216078 D1 DE 60216078D1 DE 2002616078 DE2002616078 DE 2002616078 DE 60216078 A DE60216078 A DE 60216078A DE 60216078 D1 DE60216078 D1 DE 60216078D1
Authority
DE
Grant status
Grant
Patent type
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2002616078
Other languages
English (en)
Other versions
DE60216078T2 (de )
Inventor
Huai-Hung Kao
Yadi Zeng
Michelle Howard-Sparks
Fai Jim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Pharmaceuticals Inc
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
DE2002616078 2001-05-11 2002-05-10 Opioid enthaltende arzneiform gegen missbrauch Active DE60216078D1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29043801 true 2001-05-11 2001-05-11
PCT/US2002/015021 WO2002092059A1 (en) 2001-05-11 2002-05-10 Abuse-resistant opioid dosage form

Publications (1)

Publication Number Publication Date
DE60216078D1 true DE60216078D1 (de) 2006-12-28

Family

ID=23115998

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2002616078 Active DE60216078D1 (de) 2001-05-11 2002-05-10 Opioid enthaltende arzneiform gegen missbrauch
DE2002616078 Active DE60216078T2 (de) 2001-05-11 2002-05-10 Opioid enthaltende arzneiform gegen missbrauch

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE2002616078 Active DE60216078T2 (de) 2001-05-11 2002-05-10 Opioid enthaltende arzneiform gegen missbrauch

Country Status (8)

Country Link
US (6) US20030004177A1 (de)
EP (1) EP1389092B1 (de)
JP (2) JP2005515960A (de)
CN (2) CN1592609A (de)
CA (2) CA2778114A1 (de)
DE (2) DE60216078D1 (de)
ES (1) ES2275868T3 (de)
WO (1) WO2002092059A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1041987T3 (da) 1997-12-22 2006-08-21 Euro Celtique Sa Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
ES2415407T3 (es) * 2000-02-08 2013-07-25 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク,エス.エイ. ヒドロコドン放出制御製剤
DE60216078D1 (de) * 2001-05-11 2006-12-28 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US7125561B2 (en) * 2001-05-22 2006-10-24 Euro-Celtique S.A. Compartmentalized dosage form
DE60223254D1 (de) * 2001-07-06 2007-12-13 Penwest Pharmaceuticals Co Verzögert freisetzende formulierungen von oxymorphon
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
EP1406630A1 (de) * 2001-07-06 2004-04-14 Endo Pharmaceuticals Inc. Parenterale verabreichung von hydroxy-oxymorphon als analgetikum
WO2003007802A3 (en) * 2001-07-18 2003-11-27 Christopher D Breder Pharmaceutical combinations of oxycodone and naloxone
WO2003013525A1 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
JP2005523876A (ja) * 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
CA2464528A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
KR100717591B1 (ko) 2002-04-05 2007-05-15 유로-셀띠끄 소시에떼 아노님 활성 화합물의 지속적, 불변적 및 독립적 방출용 매트릭스
WO2004026283A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
WO2004026262A3 (en) * 2002-09-23 2004-06-10 Verion Inc Abuse-resistant pharmaceutical compositions
DE10250088A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
EP2218448B1 (de) * 2002-12-13 2015-09-23 Durect Corporation Orale Darreichungsform mit flüssigen hochviskose Trägersystemen
WO2004056337A3 (en) * 2002-12-18 2004-08-19 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2519556C (en) * 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
ES2341546T3 (es) 2003-04-21 2010-06-22 Euro-Celtique S.A. Productos resistentes a la manipulacion indebida para el aporte de opioides.
CA2522529C (en) * 2003-04-30 2015-10-20 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE602004005076T2 (de) * 2003-12-09 2007-11-15 Euro-Celtique S.A. Co-extrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
EP3228308A1 (de) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alkoholresistente darreichungsformen
KR100963914B1 (ko) * 2004-03-30 2010-06-17 유로-셀띠끄 소시에떼 아노님 흡착제 및 억제제를 포함하는 내변조성 제형
US7404970B2 (en) * 2004-04-13 2008-07-29 Konec, Inc. Pain relief composition, method to form same, and method to use same
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1604667A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
WO2007013975A3 (en) * 2005-07-20 2007-04-05 David M Bear Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
FR2898056B1 (fr) * 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
KR101495146B1 (ko) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
US20100144645A1 (en) * 2006-04-14 2010-06-10 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
ES2636657T3 (es) * 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
EP2292229B1 (de) 2006-08-25 2012-05-23 Purdue Pharma LP Manipulationssichere orale pharmazeutische Dosierformen enthaltend ein Opiatanalgetikum
WO2008027442A3 (en) * 2006-08-30 2008-10-16 Theraquest Biosciences Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
EP1897544A1 (de) * 2006-09-05 2008-03-12 Holger Lars Hermann Opioid agonist und antagonisten Kombinationen
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2073797A2 (de) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmazeutische zusammensetzungen
EP2486927A1 (de) * 2007-02-12 2012-08-15 DMI Biosciences, Inc. Behandlung Frühezeitiger Comorbid-Ejakulation Und Erektiler Dysfunktion
EP2486921A1 (de) * 2007-02-12 2012-08-15 DMI Biosciences, Inc. Verringerung Der Nebenwirkungen Von Tramadol
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
CA2714921C (en) * 2007-09-04 2016-04-05 Alpharma, Inc. Pharmaceutical compositions
JP2011506319A (ja) * 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224808A4 (de) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmazeutische zusammensetzung
RU2010129907A (ru) 2007-12-17 2012-01-27 Лабофарм Инк. (CA) Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление
JP5406288B2 (ja) * 2008-07-07 2014-02-05 ユーロ−セルティーク エス.エイ. 尿閉を治療するためのオピオイド拮抗薬の使用
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010066034A8 (en) * 2008-12-12 2010-08-19 Paladin Labs Inc. Narcotic drug formulations with decreased abuse potential
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2367541B1 (de) 2008-12-16 2014-07-16 Paladin Labs Inc. Formulierung mit gesteuerter freisetzung und missbrauchsschutz
CA2754853C (en) 2009-03-10 2015-04-28 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
CA2765033A1 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CA2775890C (en) * 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2790108C (en) * 2010-02-24 2016-05-31 Cima Labs Inc. Abuse-resistant formulations
CN102946870A (zh) * 2010-05-10 2013-02-27 欧洲凯尔特公司 包含氢吗啡酮和纳洛酮的药物组合物
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク. メトプロロールを含むアルコール耐性持続放出性経口剤形
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
EP2654734A2 (de) 2010-12-22 2013-10-30 Purdue Pharma LP Gekapselte manipulationssichere darreichungsformen mit gesteuerter freisetzung
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
WO2012104752A1 (en) 2011-02-02 2012-08-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist
WO2013041851A1 (en) 2011-09-19 2013-03-28 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CN104968333A (zh) 2012-11-30 2015-10-07 阿库拉制药公司 活性药物成分的自调节释放
JP6208261B2 (ja) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップPurdue Pharma L.P. タンパリング抵抗性医薬製剤
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015089530A1 (de) * 2013-12-20 2015-06-25 G.L. PHARMA GmbH Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon
US20160243107A1 (en) * 2013-12-23 2016-08-25 Purdue Pharma L.P. Opioid Antagonist Formulations
CA2943728A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CA2955229A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1172767A (en) * 1912-12-02 1916-02-22 Levi S Couplin Fly-trap.
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5422943A (en) * 1992-09-30 1995-06-06 At&T Corp. Private branch exchange networks
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
EP2263673A1 (de) * 1993-07-01 2010-12-22 Euro-Celtique S.A. Opioidformulierungen mit verlängerter gesteuerter Wirkstoffabgabe
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
EP0871488B1 (de) * 1995-10-19 2005-04-13 The Lynx Project Limited Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
US6159501A (en) * 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
EP0914097B1 (de) * 1996-03-12 2002-01-16 Alza Corporation Zusammensetzung und dosisform mit einem opioid-antagonisten
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
EP1327447B1 (de) * 1997-09-04 2011-05-25 Novoneuron, Inc. Noribogain zur Behandlung von Schmerzen und Drogenabhängigkeit
DK1041987T3 (da) * 1997-12-22 2006-08-21 Euro Celtique Sa Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE19901687B4 (de) * 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
ES2415407T3 (es) * 2000-02-08 2013-07-25 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
DE60216078D1 (de) * 2001-05-11 2006-12-28 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2446550C (en) * 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
EP1429744A1 (de) * 2001-09-21 2004-06-23 Egalet A/S Polymeres freigabungssystem mit morphin
WO2004056337A3 (en) * 2002-12-18 2004-08-19 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DE602004005076T2 (de) * 2003-12-09 2007-11-15 Euro-Celtique S.A. Co-extrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür
WO2006124749A3 (en) * 2005-05-13 2007-05-31 Alza Corp Multilayer drug delivery system with barrier against antagonist exposure
WO2007013975A3 (en) * 2005-07-20 2007-04-05 David M Bear Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications
ES2636657T3 (es) * 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8124126B2 (en) * 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date Type
CA2778114A1 (en) 2002-11-21 application
JP2009143964A (ja) 2009-07-02 application
WO2002092059A1 (en) 2002-11-21 application
CN101439024A (zh) 2009-05-27 application
US20120237603A1 (en) 2012-09-20 application
CA2446738C (en) 2012-05-29 grant
DE60216078T2 (de) 2007-07-05 grant
US20030004177A1 (en) 2003-01-02 application
CA2446738A1 (en) 2002-11-21 application
JP2005515960A (ja) 2005-06-02 application
JP2013053165A (ja) 2013-03-21 application
EP1389092A1 (de) 2004-02-18 application
US20120231075A1 (en) 2012-09-13 application
US20110020444A1 (en) 2011-01-27 application
US20110135731A1 (en) 2011-06-09 application
ES2275868T3 (es) 2007-06-16 grant
CN1592609A (zh) 2005-03-09 application
EP1389092B1 (de) 2006-11-15 grant
US20130209561A1 (en) 2013-08-15 application

Similar Documents

Publication Publication Date Title
DK1658055T3 (da) Indgivelsesform sikret mod misbrug
DE60207576D1 (de) Injektionsvorrichtungen
DE50212382D1 (de) Ansauggeräuschdämpfer
DE50109867D1 (de) Bohrgestängebrechhilfe
DE50211814D1 (de) Faltwandcontainer
DE50200532D1 (de) Linearwegschieber
DE50203959D1 (de) Skikantenprofil
DE50212549D1 (de) Teilchenoptischer korrektor
DE50206947D1 (de) Magnetfeldschirmung
DE50209109D1 (de) Hocheinbaugargerät
DE50204607D1 (de) Nullgurt-nockenwelle
DE1319930T1 (de) Coriolismassendurchflussmesser
DE50204050D1 (de) Nachrieselschutzvorrichtung
DE50211664D1 (de) Ultraschallkernbohrkrone
DE50211605D1 (de) Eisstückchenbereiter
DE50109148D1 (de) Seilklemme
DE50212554D1 (de) Planierhobel
DE50204124D1 (de) Pumpe-düse-einheit
DE50209041D1 (de) Schliessfolgeregler
DE50201871D1 (de) Skihalle
DE50203093D1 (de) Losradlager
DE50204751D1 (de) Eikanalfahrwagen
DE10107622B4 (de) Badewannenlifter
DE50108381D1 (de) Synchronisierschaltungsanordnung
DE50203802D1 (de) Glasflügel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition